Postdoctoral Researcher
Listed on 2026-06-12
-
Research/Development
Clinical Research, Research Scientist, Medical Science, Immunology Research
Company Description
UHN is Canada’s #1 hospital and the world’s #1 publicly funded hospital. With 10 sites and more than 44,000 TeamUHN members, UHN consists of Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, The Michener Institute of Education and West Park Healthcare Centre. As Canada's top research hospital, the scope of biomedical research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care.
UHN has the largest hospital-based research program in Canada, with major research in neurosciences, cardiology, transplantation, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. UHN is a research hospital affiliated with the University of Toronto.
UHN’s vision is to build A Healthier World and it’s only because of the talented and dedicated people who work here that we are continually bringing that vision closer to reality.
Job Description
Union: Non-Union
Number of Vacancies: 1
New or Replacement Position: Replacement
Site: Princess Margaret Cancer Research Tower
Department: Research
Reports To: Principal Investigator
Salary Range: $54,902 - $93,333 Per Year
Hours: Hours Per Week
Shifts: Monday - Friday
Status: Temporary Full-time (1-Year Contract)
Closing Date: June 24, 2026
Position Summary:
A Postdoctoral Researcher position is available in the laboratory of Dr. Steven Chan at the Princess Margaret Cancer Centre. The Chan Laboratory studies the biology of acute myeloid leukemia (AML), leukemic stem cells, and clonal hematopoiesis (CH), with a strong translational focus on discovering and exploiting novel therapeutic vulnerabilities in pre-malignant and malignant myeloid cells.
This project will define the genetic and synthetic-lethal interactions of high-risk clonal hematopoiesis mutations, including TP53 and spliceosome (splicing factor) mutations, that drive the progression of CH to myelodysplastic syndromes (MDS) and AML. The successful candidate will combine genetically engineered mouse models with genome-wide and focused CRISPR/Cas9 screens to uncover context-specific dependencies in mutant hematopoietic stem and progenitor cells. The ultimate goal is to nominate new strategies to intercept high-risk clonal hematopoiesis and to prevent or treat myeloid malignancy.
Duties:
Qualifications
To Search, View & Apply for jobs on this site that accept applications from your location or country, tap here to make a Search: